Overview

A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM

Status:
Not yet recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the potential of JMT103 to treat hypercalcemia of malignancy in patients with elevated serum calcium who do not respond to recent treatment with intravenous bisphosphonates.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Shanghai JMT-Bio Inc.
Collaborator:
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.